PubMed Health⌕ Search

Biomedical subjects

N Murakami

Publications and source records attributed to N Murakami.

At least 19 recordsLinked to original sources
PubMed1997

Investigation of morphological change of lateral and midline fluid percussion injury in rats, using magnetic resonance imaging.

OBJECTIVE: Investigating the time course of morphological changes in experimental traumatic brain injury (TBI) in vivo helps to clarify the mechanism of TBI and develop new therapeutic modalities. We examined the morphological changes in experimental TBI, using magnetic resonance imaging (MRI) in a rat model. METHODS: We produced lateral fluid percussion injury (LFP) and midline fluid percussion injury (MFP) in rats, using the Yamaki fluid percussion device. The rats were divided into four groups: LFP, MFP, sham LFP, and sham MFP. MRI was performed with a 4.7-T magnetic resonance apparatus 2 days and 90 days after the induction of injury. T1-, T2-, and T2- weighted images were obtained using a surface coil. RESULTS: Hemorrhage, contusion, and brain edema in LFP models were detected on the 2nd day after injury, and the necrotic tissue was absorbed and replaced by cerebrospinal fluid on the 90th day. In MFP animals, we detected a small hemorrhage in the corpus callosum with minimal brain edema around the hemorrhage on the 2nd day after injury, and on the 90th day, enlarged ventricles and cisterns were observed, indicating brain atrophy. CONCLUSION: MRI, therefore, is useful for plotting morphological changes in experimental TBI in vivo. We report the novel and clinically important finding of brain atrophy after experimental TBI.

Animals↗
PubMed1996

Improvement of metabolic disorders and visceral fat obesity by the beta 3-adrenoceptor agonist (R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents.

The effects of BRL35135A ((R*,R*)-(+/-)-methyl-4-[2-[2-hydroxy-2 -(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide), a beta 3-adrenoceptor agonist, on visceral and subcutaneous fat weight and metabolic disorders were studied in genetically obese C57BL/KsJ db/db mice and Zucker fa/fa rats. In db/db mice, four weeks of oral administration of BRL35135A (0.5 and 5 mg/kg/day) decreased body weight gain and reduced white fat weight. The rates of reduction of white fat weight were in the order mesenteric fat > retroperitoneal fat > subcutaneous fat. In fa/fa rats, daily administration of BRL35135A (0.05 mg/kg/day)) for 6 weeks reduced the visceral white fat weight/total energy intake ratio, particularly for mesenteric fat, without any clear effect on body weight gain. This tendency of the compound to exert effects on visceral fat was consistent with the findings that the effect of BRL37344 ((R*,R*)-(+/-) -methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl]-phenoxyacet ic acid), an active metabolite of BRL35135A, on the lipolytic activity of isolated adipocytes and the tissue concentration of [14C]BRL37344 in male Wistar rats were each greater in visceral fat than in subcutaneous fat. Moreover, BRL35135A at 0.05 mg/kg/day elevated serum insulin levels and improved hyperglycemia in db/db mice without reducing body weight gain, whereas at doses of 0.5 and 5 mg/kg/day it ameliorated hyperglycemia and hyperlipidemia, and tended to decrease serum insulin levels. In fa/fa rats, BRL35135A (0.005 mg/kg/day) was also effective in improving hyperinsulinemia, glucose intolerance, and hypertriglyceridemia without any effect on body weight gain or fat distribution. These findings suggest that the improvement of metabolic disorders by BRL35135A may be due to improvement in insulin resistance as well as reduction of visceral fat weight.

Adipose Tissue↗
PubMed1996

Cerebral oxygen and glucose metabolism in glycogen storage disease with normal acid maltase: case report.

A 26-year-old male with cardiomyopathy, cervical muscle weakness and mental retardation was diagnosed as having glycogen storage disease with normal acid maltase on the basis of his clinical, pathological and biochemical findings. Positron emission tomography showed that cerebral oxygen metabolism was normal, while cerebral glucose metabolism was decreased in the cerebral cortexes. The decrease of the glucose metabolic rate may reflect an abnormality of cerebral glucose metabolism in this disorder and may be related to mental retardation, which is one of the characteristic symptoms.

Adult↗
PubMed1996

Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue.

To search for possible antitumor-promoters, two digalactosyl diacylglycerols (DGDGs), which were obtained from the freshwater cyanobacterium Phormidium tenue and possessed a single pair of acyl residues, were evaluated for their inhibitory effects on the two-stage carcinogenesis test in mouse skin. Papillomas in mouse skin were initiated with 390 nmol of 7,12-O-dimethylbenz[a]anthracene and 1 week later, were promoted twice a week with 1.7 nmol of 12-O-tetradecanoylphorbol-13-acetate (TPA). Two DGDGs effectively inhibited tumor formation in the sensitive mouse stock even when these compounds were given 1 h before TPA treatment.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1996

Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent.

Improvement of metabolic disorders by M16209 (1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin), an antidiabetic agent, was studied in genetically obese Zucker fa/fa rats and C57BL/6J ob/ob mice. In fa/fa rats oral administration of M16209 (30 and 100 mg/kg/day) for 7 days dose dependently improved hyperinsulinemia without affecting body weight. Oral glucose loading (2 g glucose/kg body weight) after 10 days of administration to fa/fa rats revealed that M16209 significantly improved glucose tolerance both 30 and 60 min after glucose loading, but did not affect preload serum glucose levels. At one day after 13 days of administration of M16209, the serum levels of triglyceride, total cholesterol and free fatty acid were clearly lower in treated fa/fa rats than those in untreated rats. In C57BL/6J ob/ob mice, M16209 given for 28 days at doses of 30 and 100 mg/kg/day improved hyperinsulinemia, hyperglycemia and hypercholesterolemia without affecting body weight. In a hyperinsulinemic euglycemic clamp study in fa/fa rats, administration of M16209 for 7 days at a dose of 100 mg/kg/day significantly normalized the decreased metabolic clearance rate but did not show any effect on the augmented hepatic glucose output. These findings demonstrate that improvement of metabolic disorders in genetically obese rodents by M16209 is due to amelioration of insulin resistance in peripheral tissues.

Administration, Oral↗
PubMed1996

Small carcinomas of the thyroid. A long-term follow-up of 867 patients.

OBJECTIVE: To determine the adequate extent of surgery for small carcinomas of the thyroid. DESIGN: Retrospective cohort study of 867 consecutive patients with small carcinomas of the thyroid (lesions < 10 mm in diameter) who were operated on at the Noguchi Thyroid Clinic, Oita, Japan, between 1965 and 1987. Mean follow-up was 12.8 years. SETTINGS: A center for treatment of thyroid disease, where about 1400 thyroid operations are performed per year. PATIENTS: Thyroidectomy was performed in patients with a preoperative diagnosis of Graves' disease, Graves' disease with nodules, solitary thyroid nodules, multinodular goiters, cysts, chronic thyroiditis and small carcinomas of the thyroid, in 394, 22, 136, 193, 18, 28, and 76 patients, respectively. RESULTS: Operations were conservative. Three patients who had adenomatous nodular goiters underwent total thyroidectomy. Modified radical neck dissection was performed in 66 patients. Of these 66 patients, 30 had grossly noticeable nodal metastases and 17 had microscopic metastases. Another 50 patients underwent selective lymph node excision, and 28 patients had nodal metastases. Recurrence from remnants of thyroid was seen in five patients. They were treated by surgery. Recurrence in lymph nodes was observed in five patients, and four of them were successfully treated. Recurrence in bone was observed in two patients; one with recurrence in the femur was successfully treated. Two patients died with recurrent cancer. CONCLUSIONS: Small carcinomas of the thyroid can be fatal. Total thyroidectomy is unnecessary. Modified radical neck dissection is unnecessary unless gross nodal metastases are present. Long-term follow-up is mandatory. A

Adolescent↗
PubMed1996

Effects of daily injections of melatonin on locomotor activity rhythms in rats maintained under constant bright or dim light.

It has been demonstrated that daily melatonin injections entrain free-running locomotor activity rhythms in rats kept in constant darkness, and synchronize disrupted circadian patterns of wheel-running activity under constant light. Contrary to these previous observations, our result did not show that daily injections of melatonin synchronize disrupted locomotor activity in rats maintained under constant bright light. On the other hand, daily treatment with melatonin entrained the intact free-running rhythm in rats kept in constant dim light. This entrainment took place only when the time of injection corresponded to the activity onset time, and similar results were obtained in blinded rats. Pinealectomy had no influences on either the free-running rhythm or melatonin-induced entrainment. To examine whether a behavioral feedback mechanism is involved in melatonin-induced entrainment, rats were immobilized for 3 h after each daily melatonin injections. This did not interfere with melatonin-induced entrainment. These results suggest that the mechanism underlying melatonin-induced entrainment of activity rhythms may be different from those in photic and behavioral entrainment.

Animals↗
PubMed1996

Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats.

The effects of M16209 (1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin) on the in vivo insulin sensitivity of rats were studied by euglycemic clamp methods after 1 week of administration (10 or 100 mg/kg/d). M16209 increased both the glucose infusion rate (GIR) and metabolic clearance rate (MCR) of 3-[3H]-glucose, but did not suppress hepatic glucose output. M16209 also increased the [3H]-2-deoxyglucose utilization rate, rate of incorporation of [14C]-glucose into glycogen, and glycolytic flux in the soleus and red gastrocnemius muscles, but not in the extensor digitorum lungus and white gastrocnemius muscles. M16209 affected neither the [3H]-2-deoxyglucose utilization rate nor the rate of incorporation of [14C]-glucose into lipids in epididymal adipose tissue. In the soleus muscle, M16209 decreased glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P) content, but did not affect fructose-1,6-bisphosphate (F-1,6-BP) content. Moreover, M16209 increased glycogen synthase-I activity and fructose-2,6-bisphosphate (F-2,6-BP) content in the soleus muscle. These results suggest that M16209 increases insulin-stimulated glucose uptake in peripheral tissues, particularly oxidative muscles, through potentiation of insulin action on glycogen synthesis and glycolysis. Glycogen synthase and phosphofructokinase (PFK) appear to be major targets of the action of M16209.

Adult↗
PubMed1996

Incidence of anaerobic infections among patients with pulmonary diseases: Japanese experience with transtracheal aspiration and immediate bedside anaerobic inoculation.

We conducted a study to assess the precise incidence of anaerobic infections among patients with pulmonary diseases in Japan. To avoid false-negative results of anaerobic cultures, we used percutaneous transtracheal aspiration and subsequent immediate bedside anaerobic inoculation onto a set of plates with appropriately selected culture media. Fifty-six episodes of pulmonary disease occurred in 50 patients; anaerobes were isolated in 20 (36%) of these episodes. Bacteria were recovered in 30 (94%) of 32 episodes not associated with prior antimicrobial therapy, and anaerobes were isolated in 15 (47%) of these 32 episodes. Rates of anaerobic isolation in episodes of pneumonia (7 of 14), lung abscess (3 of 3), and acute exacerbation of chronic lower respiratory tract infection (5 of 15) that were not associated with prior antimicrobial therapy were 50%, 100%, and 33%, respectively.

Bacteria, Anaerobic↗
PubMed1996

Mesial temporal lobe epilepsy in childhood.

To clarify the clinical picture of mesial temporal lobe epilepsy (MTLE) in childhood, we carried out a clinical, electroencephalographic, and neuroradiologic study of 19 patients. MTLE was noted in 19 (0.82%) of 2,319 epileptic patients with childhood onset. Three types of initial seizure were recognized: febrile convulsion, afebrile generalized convulsion, and complex partial seizure (CPS). As presumed causes, various prolonged convulsions (persisting for > 30 min) were found in 12 (63.2%) cases. Regardless of the presence of preceding convulsions (febrile or afebrile), the clinical course was not uniform, with CPS in the early period temporarily controlled in some cases and intractable from the early period in others. Unilateral hippocampal abnormalities were confirmed on magnetic resonance imaging (MRI) before the age of 5 years in two cases, suggesting that mesial temporal sclerosis (MTS) is formed within a relatively short period in some cases. Seizures were controlled for > 6 months in only two (10.5%) cases and persisted in 17. In four (21.1%) cases, surgical treatment was considered to be available.

Age Factors↗
PubMed1996

[Analysis of verotoxin-producing Escherichia coli (O157:H7) strains isolated in the Fukuoka area in 1994 by pulsed-field gel electrophoresis].

Nine verotoxin-producing Escherichia coli O157:H7 strains were isolated from 9 pediatric patients with sporadic enteritis between July and September 1994 at four clinics in the Fukuoka area. The patients included two families with two cases each. These strains were analyzed by pulsed-field gel electrophoresis for Xba I-digested DNA fragments. The restriction patterns were identical between each two strains within the two family outbreaks, but different among the seven strains of the distinct seven sporadic cases. It is strongly suggested that the seven sporadic cases were infected through distinct sources, and that the two family cases were due to a common source of infection or person to person infection.

Bacterial Toxins↗
PubMed1996

Plasma and neurohypophyseal content of vasopressin in diabetes mellitus.

Vasopressin (VP) hypersecretion is known to occur in diabetes mellitus. Using magnetic resonance (MR) imaging, we evaluated the VP content of the posterior lobe of the pituitary gland in 22 patients with uncontrolled noninsulin-dependent diabetes mellitus. The mean VP level and hemoglobin A1c value were elevated; 6.8 +/- 6.8 pg/mL (normal, 0.3-3.5) and 11.7 +/- 2.1% (normal, < 6%). The signal intensity ratio of the posterior lobe to the pons was calculated on a MR T1-weighted image where the signal intensity reflects VP content and the posterior lobe has a characteristic hyperintense signal under normal conditions. The mean signal intensity ratio (1.34 +/- 0.22) was lower than that in 20 healthy subjects (1.56 +/- 0.13; P < 0.01). In 7 cases, the signal intensity ration was markedly decreased, and the hyperintense signal was absent. The hyperintense signal appeared after diabetic control in all 6 subjects who underwent follow-up MR examinations within 1-2 months. The VP content in the posterior lobe was decreased in patients with uncontrolled diabetes mellitus, which was thought to be caused by persistent VP hypersecretion. The persistent elevation of plasma VP might have some role in the initiation and progression of diabetic complications.

Adult↗
PubMed1996

Acceleration of glycolysis in erythrocytes by the antidiabetic agent M16209.

The effects of M16209 (1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin), an antidiabetic agent and aldose reductase inhibitor, on glycolysis were studied in rat and human erythrocytes in vitro. M16209 increased lactate production from glucose when incubated with rat and human erythrocytes, and also increased glucose consumption in rat erythrocytes. The rates of production of lactate in rat erythrocytes treated with M16209 at 10, 25 and 50 microM were 113, 118 and 123%, respectively, of those in vehicle treated cells. Sorbinil (aldose reductase inhibitor), tolbutamide (sulfonylurea), and buformine (biguanide) did not increase lactate production in rat erythrocytes when tested at 50 microM. On the other hand, M16209 did not affect lactate production from D-glyceraldehyde in rat erythrocytes. At 100 microM the agent decreased both glucose-6-phosphate and fructose-6-phosphate in rat erythrocytes, and increased fructose-1,6-bisphosphate; at 10 microM it also increased 6-phosphofructokinase activity in rat hemolysates. These findings suggest that M16209 accelerates glycolysis in erythrocytes via activation of 6-phosphofructokinase.

Aldehyde Reductase↗
PubMed1996

Medicinal foodstuff. III. Sugar beet. (1): Hypoglycemic oleanolic acid oligoglycosides, betavulgarosides I, II, III, and IV, from the root of Beta vulgaris L. (Chenopodiaceae).

Betavulgarosides I, II, III, and IV, oleanolic acid oligoglycosides having an unique acidic substituent, were isolated from the root of Beta vulgaris L. (sugar beet) together with betavulgarosides VI, VII, and VIII. The chemical structures of betavulgarosides I, II, III, IV were identified from chemical and physicochemical evidence. Betavulgarosides II, III, and IV were found to exhibit hypoglycemic activity in an oral glucose tolerance test in rats.

Animals↗
PubMed1996

New bioactive monoterpene glycosides from Paeoniae Radix.

Bioassay-guided separation of MeOH extract of Japanese Paeoniae Radix inhibiting contractile responses of guinea pig ileum stimulated with electric field disclosed a new monoterpene glycoside, 6-O-beta-D-glucopyranosyl-lactinolide (1), as an active constituent together with two new monoterpene glycosides (3 and 4) and two new monoterpenes (2 and 5). Furthermore, 1-O-beta-D-glucopyranosyl-paeonisuffrone (2) was found to inhibit histamine release from rat peritoneal exudate cells induced by antigen-antibody reaction.

Animals↗
PubMed1996

Bioactive saponins and glycosides. II. Senegae Radix. (2): Chemical structures, hypoglycemic activity, and ethanol absorption-inhibitory effect of E-senegasaponin c, Z-senegasaponin c, and Z-senegins II, III, and IV.

Following the characterization of E-senegasaponins a and b and Z-senegasaponins a and b, new bioactive saponins named E-senegasaponin c and Z-senegasaponin c were isolated from Senegae Radix, the root of Polygala senega L. var. latifolia TORREY et GRAY., together with Z-senegins II, III, and IV. The chemical structures of E and Z-senegasaponins c and Z-senegins II, III, and IV were elucidated on the basis of chemical and physicochemical evidence, and the geometrical isomeric structures of the 4"-methoxycinnamoyl and 3",4"-dimethoxycinnamoyl groups in these saponins were found to show tautomer-like behavior under irradiation with fluorescent lamps. E and Z-Senegasaponins c and E and Z-senegins II, III, and IV were found to exhibit hypoglycemic activity in the oral D-glucose tolerance test. (E) and (Z)-Senegins II also showed an inhibitory effect on alcohol absorption in rats.

Absorption↗
PubMed1996

Antitumor-promoting activities of various synthetic 1-O-acyl-3-O-(6'-O-acyl-beta-D-galactopyranosyl)-sn-glycerols related to natural product from freshwater cyanobacterium Anabaena flos-aquae f. flos-aquae.

1-O-Acyl-3-O-(6'-O-acyl-beta-D-galactopyranosyl)-sn-glycerol, which was isolated from a nitrogen-fixing fresh water cyanobacterium, Anabaena flos-aquae f. flos-aquae, was synthesized by utilizing lipase-catalyzed acylation. The antitumor-promoting activities of these galactolipids were evaluated using a short-term in vitro assay of Epstein-Barr virus activation in Raji cells induced by 12-O-tetradecanoyl- phorbol 13-acetate (TPA). The glyceroglycolipids which have a palmitoleoyl residue at the 1-O-position exhibited more potent activities than the others in this assay.

Anabaena↗